Mizuho lowered the firm’s price target on Ardent Health (ARDT) to $18 from $19 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health initiated with a Buy at Guggenheim
- Ardent Health Partners, Inc.: Buy Rating Affirmed on Adjusted Earnings Forecast and Stable Financial Outlook
- Ardent Health Partners Expands Board with New Appointment
- Ardent Health Partners Appoints New Chief Operating Officer
- Ardent Health names Dave Caspers COO